(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 October 2022 (13.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/214014 A1

(51) International Patent Classification:
A61K 35/76 (2015.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/CN2022/085474

(22) International Filing Date:
07 April 2022 (07.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2021/085930
08 April 2021 (08.04.2021) CN
PCT/CN2021/106319
14 July 2021 (14.07.2021) CN

(71) Applicant: **IMMVIRA BIOPHARMACEUTICALS CO., LIMITED** [CN/CN]; Room 1606, 16F, Block 5, Building 3, No. 111 Wusongjiang, Avenue, Wuzhong District, Suzhou, Jiangsu 215124 (CN).

(72) Inventors: **CHEN, Xiaoqing**; C/O IMMVIRA BIOPHARMACEUTICALS CO., LIMITED, Room 1606, 16F, Block 5, Building 3, No. 111 Wusongjiang, Avenue, Wuzhong District, Suzhou, Jiangsu 215124 (CN). **LIU, Yuanyuan**; C/O IMMVIRA BIOPHARMACEUTICALS CO., LIMITED, Room 1606, 16F, Block 5, Building 3, No. 111 Wusongjiang, Avenue, Wuzhong District, Suzhou, Jiangsu 215124 (CN). **LIU, Ziwen**; C/O IMMVIRA BIOPHARMACEUTICALS CO., LIMITED, Room 1606, 16F, Block 5, Building 3, No. 111 Wusongjiang, Avenue, Wuzhong District, Suzhou, Jiangsu 215124 (CN). **DENG, Tianyi**; C/O IMMVIRA BIOPHARMACEUTICALS CO., LIMITED, Room 1606, 16F, Block 5, Building 3, No. 111 Wusongjiang, Avenue, Wuzhong District, Suzhou, Jiangsu 215124 (CN). **ZHOU, Grace Guoying**; C/O IMMVIRA BIOPHARMACEUTICALS CO., LIMITED, Room 1606, 16F, Block 5, Building 3, No. 111 Wusongjiang, Avenue, Wuzhong District, Suzhou, Jiangsu 215124 (CN).

(74) Agent: **WINGUAN PATENT AND TRADEMARK ATTORNEYS**; Tower A 2317, China Shine Plaza, 9 Linhe Xi Road, Tianhe District, Guangzhou, Guangdong 510610 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/214014 A1

(54) Title: GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS DELIVERING CHEMOKINE AND TUMOR ASSOCIATED/SPECIFIC ANTIGEN

(57) Abstract: Disclosed is a genetically modified oncolytic herpes simplex virus (oHSV) encoding a truncated nonsignaling variant of at least one tumor associated/specific antigen, and at least one chemokine. The expression of the truncated nonsignaling variant and the chemokine is under the control of an immediate-early gene promoter of HSV, and the truncated nonsignaling variant is expressed and presented on a tumor cell surface as a biomarker upon replication of the oHSV in the tumor cell, and the chemokine is expressed and released to induce chemotaxis of an immune cell towards the tumor cell. The genetically modified oHSV can be used in combination with CAR-T, ADC, and/or BiTE therapies.